Last reviewed · How we verify
aripiprazole , sertraline
At a glance
| Generic name | aripiprazole , sertraline |
|---|---|
| Sponsor | Chimei Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) (PHASE4)
- Pragmatic Trial of Obsessive-compulsive Disorder (PHASE2)
- Personalized Indications for CBT and Antidepressants in Treating Depression (PHASE4)
- Psychoeducational Group for Depression (NA)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aripiprazole , sertraline CI brief — competitive landscape report
- aripiprazole , sertraline updates RSS · CI watch RSS
- Chimei Medical Center portfolio CI